{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:49:43Z","timestamp":1794664183256,"version":"4.9.1"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:p> <jats:italic>Cryptosporidium<\/jats:italic> is a common cause of gastroenteritis and is associated with severe life\u2010threatening illness among immunocompromised individuals. This review aimed to assess the efficacy of interventions for the treatment and prevention of cryptosporidiosis among immunocompromised patients. A search of Medline, Embase and other electronic databases was carried out up to August 2005. Two reviewers independently extracted data and assessed study quality. The relative risk for each intervention was calculated. Seven trials involving 169 participants were included. Nitazoxanide and paramomycin were associated with a relative risk (RR) of reduction in the duration and frequency of diarrhoea of 0.83 [95% confidence interval (CI) 0.36, 1.94] and 0.74 (95% CI 0.42, 1.31), respectively, showing no evidence of effectiveness. Nitazoxanide led to significant evidence of oocyst clearance compared with placebo with a RR of 0.52 (95% CI 0.30, 0.91). The effect was not significant for HIV\u2010seropositive participants (RR 0.71, 95% CI 0.36, 1.37). HIV\u2010seronegative participants on nitazoxanide had a significantly higher relative risk of achieving parasitological clearance of 0.26 (95% CI 0.09, 0.80) based on a single study. No other intervention was associated with either a reduction in diarrhoea, mortality or a significant parasitological response. This review confirms the absence of evidence for effective agents in the management of cryptosporidiosis. The results indicate that nitaxozanide reduces load of parasites and may be useful in immunocompetent individuals. The absence of effective therapy highlights the importance of preventive interventions in this group of patients.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2007.02873.x","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T11:50:11Z","timestamp":1172836211000},"page":"387-393","source":"Crossref","is-referenced-by-count":193,"title":["Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"63","author":[{"given":"I.","family":"Abubakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Aliyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. K.","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.1.145-154.2002"},{"key":"e_1_2_6_3_2","volume-title":"Guidelines for Drinking Water Quality Water Borne Pathogens","author":"Havelaar A","year":"2003"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268897007589"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199407213310304"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.11.3984-3990.2000"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.4.3.325"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07529-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050461"},{"key":"e_1_2_6_10_2","unstructured":"AbubakarI AliyuSH ArumugamC HunterP UsmanN.Prevention and treatment of cryptospordiosis in immunocompromised patients.Cochrane Database Syst Rev2007;24: CD004932."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1999.11.5.391"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.51.2.138"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012220-00010"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.suppl_2.85"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89499-5"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/515352"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.suppl_2.93"},{"key":"e_1_2_6_19_2","first-page":"136","article-title":"Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium","volume":"8","author":"Saez\u2010Llorens X","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/321008"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/516374"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.01109773"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198712000-00005"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199612010-00008"},{"key":"e_1_2_6_25_2","first-page":"179","article-title":"Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease","volume":"48","author":"Kadappu KK","year":"2002","journal-title":"J Postgrad Med"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11401-2"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.1.108"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.1.131"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/318155"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(98)90804-5"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199006000-00015"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.2.419"},{"key":"e_1_2_6_33_2","first-page":"717","article-title":"Cryptosporidiosis in Benha, study of some recent modalities in diagnosis and treatment","volume":"30","author":"Abdel\u2010Maboud AI","year":"2000","journal-title":"J Egypt Soc Parasitol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01253-8"},{"key":"e_1_2_6_35_2","first-page":"24","article-title":"Advice on the response from public and environmental health to the detection of cryptosporidial oocysts in treated drinking water. PHLS Advisory Committee on Water and the Environment","volume":"3","author":"Hunter PR","year":"2000","journal-title":"Commun Dis Public Health"},{"key":"e_1_2_6_36_2","first-page":"7","article-title":"Cryptosporidium in water. CDC Guidelines on How to Protect Yourself. Centers for Disease Control and Prevention","author":"CDC.","year":"1995","journal-title":"AIDS Treat. News"},{"key":"e_1_2_6_37_2","first-page":"1","article-title":"Guidelines for preventing opportunistic infections among HIV\u2010infected persons \u2013 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America","volume":"51","author":"Kaplan JE","year":"2002","journal-title":"MMWR Recomm Report"},{"key":"e_1_2_6_38_2","first-page":"726","article-title":"Resolution of AIDS associated cryptosporidiosis after treatment with indinavir","volume":"92","author":"Grube H","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200010010-00006"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(01)02205-X"},{"key":"e_1_2_6_41_2","volume-title":"Principles and Practice of Infectious Diseases","year":"2005"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.1959"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-7646(02)00011-0"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1094786"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0304686101"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407121200"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2007.02873.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2007.02873.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:00:15Z","timestamp":1697425215000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2007.02873.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1365-2125.2007.02873.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02873.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}